bluebird bio, Inc. (BLUE): Price and Financial Metrics

bluebird bio, Inc. (BLUE): $3.04

0.16 (-5.00%)

POWR Rating

Component Grades








Add BLUE to Watchlist
Sign Up

Industry: Biotech




#292 of 359

in industry

BLUE Price/Volume Stats

Current price $3.04 52-week high $8.58
Prev. close $3.20 52-week low $2.78
Day low $3.04 Volume 2,903,400
Day high $3.23 Avg. volume 4,236,373
50-day MA $3.57 Dividend yield N/A
200-day MA $4.61 Market Cap 325.14M

BLUE Stock Price Chart Interactive Chart >


  • Growth is the dimension where BLUE ranks best; there it ranks ahead of 86.3% of US stocks.
  • BLUE's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • BLUE's current lowest rank is in the Stability metric (where it is better than 1.36% of US stocks).

BLUE Stock Summary

  • Of note is the ratio of BLUEBIRD BIO INC's sales and general administrative expense to its total operating expenses; 98.74% of US stocks have a lower such ratio.
  • With a price/sales ratio of 36.28, BLUEBIRD BIO INC has a higher such ratio than 95.93% of stocks in our set.
  • As for revenue growth, note that BLUE's revenue has grown -171.58% over the past 12 months; that beats the revenue growth of merely 0.19% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to BLUEBIRD BIO INC, a group of peers worth examining would be AGIO, AFIB, CRSP, XBIT, and RVMD.
  • BLUE's SEC filings can be seen here. And to visit BLUEBIRD BIO INC's official web site, go to

BLUE Valuation Summary

  • BLUE's EV/EBIT ratio is -4.7; this is 137.9% lower than that of the median Healthcare stock.
  • BLUE's price/sales ratio has moved down 389.5 over the prior 125 months.

Below are key valuation metrics over time for BLUE.

Stock Date P/S P/B P/E EV/EBIT
BLUE 2023-09-18 36.3 1.2 -3.6 -4.7
BLUE 2023-09-15 38.1 1.2 -3.7 -4.8
BLUE 2023-09-14 37.9 1.2 -3.7 -4.8
BLUE 2023-09-13 37.9 1.2 -3.7 -4.8
BLUE 2023-09-12 39.6 1.3 -3.9 -5.0
BLUE 2023-09-11 40.5 1.3 -4.0 -5.0

BLUE Growth Metrics

    The year over year price growth rate now stands at -88.6%.
  • Its 3 year net income to common stockholders growth rate is now at -21.62%.
  • Its 4 year net income to common stockholders growth rate is now at -199.98%.
Over the past 15 months, BLUE's revenue has gone down $85,993,000.

The table below shows BLUE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 -35.746 -436.405 -453.862
2022-06-30 -13.14 -506.318 -594.158
2022-03-31 -7.187 -557.608 -735.722
2021-12-31 3.662 -635.639 -819.378
2021-09-30 53.651 -651.107 -864.2
2021-06-30 50.247 -652.948 -842.129

BLUE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BLUE has a Quality Grade of D, ranking ahead of 15.84% of graded US stocks.
  • BLUE's asset turnover comes in at 0.029 -- ranking 353rd of 682 Pharmaceutical Products stocks.
  • NERV, OTLC, and BPMC are the stocks whose asset turnover ratios are most correlated with BLUE.

The table below shows BLUE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.029 0.594 -0.648
2021-03-31 0.129 0.972 -0.495
2020-12-31 0.136 0.978 -0.496
2020-09-30 0.137 0.980 -0.528
2020-06-30 0.132 0.981 -0.546
2020-03-31 0.030 0.934 -0.590

BLUE Price Target

For more insight on analysts targets of BLUE, see our BLUE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $82.33 Average Broker Recommendation 1.92 (Hold)

bluebird bio, Inc. (BLUE) Company Bio

Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.

BLUE Latest News Stream

Event/Time News Detail
Loading, please wait...

BLUE Latest Social Stream

Loading social stream, please wait...

View Full BLUE Social Stream

Latest BLUE News From Around the Web

Below are the latest news stories about BLUEBIRD BIO INC that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12 months. CRISPR Therapeutics doesn't have any approved treatments on the market yet, but that'll change soon enough, which is the crux of the thesis in favor of it being a great growth stock. Through its partnership with Vertex Pharmaceuticals, it's aiming to commercialize the gene therapy exa-cel, which was developed to provide a functional cure for both beta-thalassemia and sickle cell disease.

Yahoo | September 20, 2023

More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics

Gene editing is a relatively new technology that allows scientists to modify an organism's DNA. Two companies that are hard at work in this field are Bluebird Bio (NASDAQ: BLUE) and CRISPR Therapeutics (NASDAQ: CRSP). Bluebird Bio currently has two approved gene-editing therapies on the market.

Yahoo | September 12, 2023

2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street

Investors looking for stocks that can put up dramatic gains in a short amount of time naturally flock to biotech stocks. Up and down Wall Street, the investment bank analysts have been telling anyone who'll listen to buy these biotech stocks before they soar. The average price target on these stocks suggests some dramatic gains could be up ahead.

Yahoo | September 12, 2023

Bluebird (BLUE) Up 7.3% Since Last Earnings Report: Can It Continue?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 7, 2023

bluebird bio Announces September Investor Events

SOMERVILLE, Mass., September 05, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:

Yahoo | September 5, 2023

Read More 'BLUE' Stories Here

BLUE Price Returns

1-mo -14.61%
3-mo -10.06%
6-mo -32.59%
1-year -45.91%
3-year -94.57%
5-year -97.82%
YTD -56.07%
2022 -30.73%
2021 -76.91%
2020 -50.69%
2019 -11.54%
2018 -44.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!